Peoples Bank KS acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,895 shares of the company's stock, valued at approximately $1,102,000.
Other large investors have also recently bought and sold shares of the company. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $25,000. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth $26,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC acquired a new stake in Cencora in the first quarter valued at about $30,000. Finally, LRI Investments LLC acquired a new stake in Cencora in the first quarter valued at about $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages recently commented on COR. StockNews.com downgraded shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Robert W. Baird reduced their price objective on Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research report on Friday, September 6th. Bank of America restated a "neutral" rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Wells Fargo & Company boosted their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.67.
Read Our Latest Analysis on COR
Cencora Trading Down 0.5 %
Shares of COR stock traded down $1.02 during trading hours on Friday, hitting $219.94. 1,638,139 shares of the company were exchanged, compared to its average volume of 1,415,768. The company has a 50 day simple moving average of $234.76 and a two-hundred day simple moving average of $232.34. The firm has a market cap of $43.87 billion, a P/E ratio of 24.18, a P/E/G ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a fifty-two week low of $182.62 and a fifty-two week high of $247.66.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.92 EPS. Equities analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.
Cencora Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%.
Insider Transactions at Cencora
In related news, EVP Silvana Battaglia sold 1,473 shares of the company's stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the business's stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 over the last ninety days. 15.80% of the stock is currently owned by insiders.
Cencora Company Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
